Widgetized Section

Go to Admin » Appearance » Widgets » and move Gabfire Widget: Social into that MastheadOverlay zone

Stellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology

Published Monday March 13

– Stellar to receive upfront fee and future royalties

Stellar advanced this technology through exploratory preclinical studies completed under an exclusive license of the patented immunotherapy technology from the University of Guelph , Canada. Stellar President and CEO Frank Oakes said that Matrivax’s acquisition of Stellar’s interest in C. diff technology underscores the…

Article length: About 950 words.
Tags: Patenting Acquisitions Purchase Sale
Read more at Medindia